Definium Therapeutics (DFTX) Non-Current Assets (2021 - 2026)

Definium Therapeutics (DFTX) has 6 years of Non-Current Assets data on file, last reported at $20.7 million in Q1 2026.

• Non-Current Assets for Q1 2026 came in at $20.7 million, down 61.34% year-over-year; the trailing twelve-month figure through Mar 2026 was $138.5 million (up 20.45% YoY), and the FY2025 annual result was $20.8 million, up 1.21% from the prior year.
• Non-Current Assets was little changed at $20.7 million in Q1 2026 per DFTX's latest filing, from $20.8 million in the prior quarter.
• Over five years, Non-Current Assets peaked at $76.0 million in Q2 2025 and troughed at $20.1 million in Q1 2024.
• A 5-year average of $27.1 million and a median of $21.5 million in 2023 frame the typical range for Non-Current Assets.
• The sharpest annual moves came in 2025 and 2026: Non-Current Assets surged 271.38% in 2025, then plunged 61.34% in 2026.
• A 5-year view of Non-Current Assets shows it stood at $23.9 million in 2022, then slipped by 13.66% to $20.7 million in 2023, then dropped by 0.67% to $20.5 million in 2024, then increased by 1.21% to $20.8 million in 2025, then declined by 0.24% to $20.7 million in 2026.
• Business Quant data shows DFTX's Non-Current Assets at $20.7 million in Q1 2026, $20.8 million in Q4 2025, and $21.1 million in Q3 2025.